As of 9:54am ET
| -0.07 / -1.01%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 9.38, with a high estimate of 10.00 and a low estimate of 8.77. The median estimate represents a +37.19% increase from the last price of 6.84.
The current consensus among 3 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.